Kohjin Bio

177A.TPharmaceutical
Financials · Standalone

From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 1
PeriodFormFiledFigures
2025-04-01 → 2026-03-31Annual2026-06-23201 figures · EDINET
Segments · FY ended 2026-03
SegmentExternal salesProfit
Cell Process Business¥975m¥80m
Microbiological Business¥1.4bn−¥95m
Tissue Culture Business¥2.5bn¥946m
Adjustments & eliminations—−¥590m
Total¥4.9bn¥932m

Segment names from EDINET member IDs; not mapped to a common taxonomy.